Revolver Peptides - antagonising an "undruggable" transcription factor

Revolver 肽 - 拮抗“不可成药”的转录因子

• 批准号: 10073940
• 金额: $ 6.31万
• 依托单位: REVOLVER THERAPEUTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10073940
• 关键词: Revolver; Peptides; antagonising; undruggable; transcription

Revolver Tx is developing novel peptide-based inhibitors of transcription factors, which were previously thought to be intractable drug targets and are critical to the proliferation of cancer cells. Our project is focused on evaluating a functional inhibitor capable of removing transcription factors from DNA by conducting preclinical efficacy studies to validate our technology platform. Consequently, Revolver Peptides are focused on drugging "undruggable" transcription factors by using engineering biology technology. Our initial therapeutic focus is on cancer.According to the World Health Organisation, cancer is a leading cause of death worldwide and accounted for nearly 10 million deaths in 2020, with the number of new cancer cases is expected to rise by 70% over the next two decades. In the UK, there are more than 360,000 new cancer cases every year, which is 990 every day. Every two minutes someone in the UK is diagnosed with cancer. Although historic investment in research has resulted in cancer survival rates improving, not all forms of the disease have seen such progress, and, for some cancers, long-term survival rates have not changed for decades. Consequently, there is an urgent need for a robust platform to transform drug screening, leading to improvements over current treatment options.Across the pharmaceutical industry, potential new cancer drugs dominate their pipeline, comprising at least one third of all drugs currently in development, which has continued to grow each year. Almost 7,000 new cancer products were in development globally, double the total of the next largest therapeutic area. We believe the pharmaceutical industry's appetite for differentiated early-stage cancer assets will continue to grow for at least the next five years and, probably, well beyond.Fed by these unprecedented levels of investment, the pharmaceutical industry remains hungry for truly differentiated drug discovery programmes and their underpinning platform technologies. Consequently, pharmaceutical companies continue to adopt a strategic approach to the outsourcing of innovative R&D requirements to specialist partners by in licensing of early-stage therapeutic products. This established strategy is motivated by the observation that current internal drug pipelines are failing to meet the expected growth demands for discovering cost-effective new therapies without supplementing this with externally sourced innovation. The vision for Revolver is to become a global market leader in providing drug discovery solutions and early-stage therapeutic assets to the pharmaceutical industry by commercially exploiting unique protein-DNA screens generating Revolver Peptides as research tools to enable the discovery of innovative new therapeutics.

Revolver Tx正在开发基于肽的新型转录因子抑制剂，这些转录因子以前被认为是难以治疗的药物靶点，对癌细胞的增殖至关重要。我们的项目专注于通过进行临床前疗效研究来评估能够从DNA中去除转录因子的功能性抑制剂，以验证我们的技术平台。因此，Revolver Peptides致力于利用工程生物学技术对“非药物性”转录因子进行药物化。根据世界卫生组织的数据，癌症是全球主要的死亡原因，于二零二零年约有1，000万人死于癌症，预计未来二十年癌症新症数目将增加70%。在英国，每年有超过360，000个新的癌症病例，每天有990个。在英国，每两分钟就有一个人被诊断出患有癌症。虽然历史上对研究的投资导致癌症存活率的提高，但并非所有形式的疾病都有这样的进展，对于某些癌症，长期存活率几十年来没有改变。因此，迫切需要一个强大的平台来改变药物筛选，从而改善当前的治疗选择。在整个制药行业，潜在的新癌症药物占据了他们的管道，占目前正在开发的所有药物的至少三分之一，并且每年都在持续增长。全球有近7，000种新的癌症产品正在开发中，是第二大治疗领域的两倍。我们认为，制药行业对差异化早期癌症资产的需求至少在未来五年内将继续增长，甚至可能远远超过这一水平。在这些前所未有的投资水平的推动下，制药行业仍然渴望真正差异化的药物发现计划及其基础平台技术。因此，制药公司继续采取战略方法，通过许可早期治疗产品，将创新研发要求外包给专业合作伙伴。这一既定战略的动机是观察到，目前的内部药物管道未能满足发现具有成本效益的新疗法的预期增长需求，而无需外部来源的创新来补充。Revolver的愿景是成为全球市场领导者，为制药行业提供药物发现解决方案和早期治疗资产，通过商业化利用独特的蛋白质-DNA筛选产生Revolver肽作为研究工具，以发现创新的新疗法。